Ten Billion dollar M&A - Big Pharma betting on AI Designed Drugs that challenge Nature's evolution

Ten Billion dollar M&A - Big Pharma betting on AI Designed Drugs that challenge Nature's evolution. This podcast analyzes how agentic AI is becoming the fundamental operating layer for the modern biotech industry. It outlines a structural shift toward the "Three-Stack Era," where major drug developers are consolidating their research and infrastructure around foundation models from OpenAI, Anthropic, or Google DeepMind. The text illustrates this transition through high-stakes evidence, such as Eli Lilly’s multi-billion dollar investment in AI-designed gene editors and Bristol Myers Squibb’s massive enterprise-wide deployment of AI agents. Ultimately, the document provides a strategic roadmap for industry leaders, connecting record-breaking M&A activity and novel clinical breakthroughs to an imminent regulatory landscape defined by new FDA guidance on artificial intelligence.